SavedAdd your journal

Journals / Bakırköy Tıp Dergisi / 2010 / Cilt: 6 - Sayı: 1

Importance of jak-2 gene mutation in the diagnosis of polycythemia vera: A case report and review of the literature

Polisitemia vera tanısında jak-2 gen mutasyonunun önemi: Olgu sunumu ve literatürün gözden geçirilmesi

Hasan MAĞIN
M. Fatih AKDOĞAN
Çetin UYANIK
Murat GÜCÜN
Fatih PALİT
Murat DURANAY
Pages
35–38
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

A slight overall male predominance has been observed, but females predominate within the reproductive age range.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Polycythemia vera is an acquired myeloproliferative disorder that causes overproduction of all three hematopoietic cell lines, most promi- nently the red blood cells.
📊
Key Findings & Data:The most common of the chronic myeloproliferative disorders, polycythemia vera occurs in about 0,5-2 per 100,000 persons.
💡
Conclusion & Impact:A slight overall male predominance has been observed, but females predominate within the reproductive age range.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Polycythemia vera is an acquired myeloproliferative disorder that causes overproduction of all three hematopoietic cell lines, most promi- nently the red blood cells. The most common of the chronic myeloproliferative disorders, polycythemia vera occurs in about 0,5-2 per 100,000 persons. A slight overall male predominance has been observed, but females predominate within the reproductive age range. In this case report, We aimed to emphasize that cytogenetic analysis recently is important in the diagnosis of polycythemia vera.

Özet

Polisitemia vera ön planda eritrosit olmak üzere her üç hematopoetik hücre dizisinin aşırı üretimi ile sonuçlanan edinsel bir myeloproliferatif hastalıktır. Kronik myeloproliferatif hastalıklar içerisinde en sık görülen polisitemia vera, 100000’de 0,5-2 oranında görülür. Genel anlamda hafif erkek üstünlüğü gözlense de, üretken yaş aralığı bayanlarda bir baskınlık mevcuttur. Bu olgu sunumundaki amacımız, sitogenetik analizin son zamanlarda polisitemia vera tanısındaki önemini vurgulamaktır.

🔖

Cite This Article

MAĞIN, H., AKDOĞAN, M. F., UYANIK, Ç., GÜCÜN, M., PALİT, F., DURANAY, M. (2010). Importance of jak-2 gene mutation in the diagnosis of polycythemia vera: A case report and review of the literature. Bakırköy Tıp Dergisi, Cilt: 6 - Sayı: 1, 35–38. https://ajindex.com/articles/130764

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Spivak JL. Polychtemia vera: myth, mechanism and management. Blood 2002; 100: 4272-4290
  2. Tefferi A, Solberg LA, Silverstein MN. A clinical update in polychtemia vera and essential thrombocythemia. Am J Med 2000; 109: 141-149
  3. Messinezy M, Pearson TC. The classification and diagnostic criteria of the erythrocytoses (polychtemias). Clin Lab Haematol 1999; 21: 309-316
  4. Tefferi A, Lasho TL, Gilliland G. JAK-2 mutations in myeloproliferative disorders. N Engl J Med 2005; 353: 1416-1417
  5. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK-2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790
  6. Balduini CL, Bertolino G, Noris P, Piletta GC. Platelet aggregation in platelet rich plasma and whole blood in 120 patients with myeloproliferative disorders. Am J Clin Pathol 1991; 95: 82-86
  7. Buss DH, Stuart JJ, Lipscomb GE. The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: An analysis of 129 cases. Am J Hematol 1985; 20: 365-372
  8. Tefferi A. Polychtemia vera: A comprehensive review and clinical recommendations. Mayo Clin Proc 2003; 78: 174-194
  9. Manoharan A, Garson OM. Familial polycythemia vera: a study of 3 sisters. Scand J Haematol 1976; 17: 10-16
  10. Brubaker LH, Wasserman LR, Goldberg JD, et al. Increased prevalance of polycythemia vera in parents of patients on polycythemia vera study group protocols. Am J Hematol 1984; 16: 367-373
  11. Osler W. Chronic cyanosis with polycthemia and enlarged spleen: a new clinical entity. Am J Medic Scien 1903; 126: 176-201
  12. Pearson TC. Evaluation of diagnostic criteria in polycythemia vera. Semin Hematol 2001; 38: 21-24
  13. Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol. 1975; 12: 339-351
  14. Michiels JJ, Juvonen E. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Trombocythemia Vera Study Group. Semin Thromb Hemost. 1997; 23: 339-347
  15. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365: 1054-1061
  16. Lippert E, Boissinot M, Kralovics R, et al. The JAK-2(V617F) mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 2006; 108: 1865-1867
  17. Finazzi G, Barbui T. How I treat patients with polycythemia vera. Blood 2007; 109: 5104-5111
  18. Spivak JL. The optimal management of Polych